Allon Therapeutics, Inc. (“Allon”), a privately held biotechnology company focused on neurodegenerative diseases, announced today the first closing of its $2.5 million Series A round. This investment will allow the company to complete preclinical development of its lead product and fund early stage clinical trials. This product has been demonstrated to produce neuroprotective action in disease models related to Alzheimer’s, Parkinson’s, multiple sclerosis, and fetal alcohol syndrome.
